111
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Murine Leukemia-Derived Extracellular Vesicles Elicit Antitumor Immune Response

, , , , ORCID Icon &
Pages 277-285 | Published online: 17 May 2021

References

  • Colvin GA, Berz D, Ramanathan M, et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant. 2009;15(4):421–431. doi:10.1016/j.bbmt.2008.12.503
  • Burdach S, Kolb HJ. The vigor of defense against non-self: potential superiority of allorestricted T cells in immunotherapy of cancer? Front Oncol. 2013;3:100. doi:10.3389/fonc.2013.00100
  • Kumari S, Walchli S, Fallang LE, et al. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc Natl Acad Sci U S A. 2014;111(1):403–408. doi:10.1073/pnas.1306549111
  • Paciucci PA, Macphail S, Zarling JM, Bach FH. Lysis of syngeneic solid tumor cells by alloantigen stimulated mouse T and non-T cells. J Immunol. 1980;124(1):370–375.
  • Schirrmacher V, Hubsch D, Garrido F. Syngeneic tumor cells can induce alloreactive T killer cells: a biological role for transplantation antigens. Proc Natl Acad Sci U S A. 1980;77(9):5409–5413. doi:10.1073/pnas.77.9.5409
  • Sensi ML, Parenza M, Parmiani G. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells. J Natl Cancer Inst. 1983;70(2):291–297.
  • Stauss HJ, Xue S, Gillmore R, et al. Exploiting alloreactivity for tumour immunotherapy. Vox Sang. 2004;87(Suppl 2):227–229. doi:10.1111/j.1741-6892.2004.00493.x
  • Pando A, Reagan JL, Nevola M, Fast LD. Induction of anti-leukemic responses by stimulation of leukemic CD3+ cells with allogeneic stimulator cells. Exp Hematol Oncol. 2018;7:25. doi:10.1186/s40164-018-0118-5
  • Pando A, Reagan JL, Quesenberry P, Fast LD. Extracellular vesicles in leukemia. Leuk Res. 2018;64:52–60. doi:10.1016/j.leukres.2017.11.011
  • Mahaweni NM, Kaijen-Lambers ME, Dekkers J, Aerts JG, Hegmans JP. Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J Extracell Vesicles. 2013;2. doi:10.3402/jev.v2i0.22492
  • Simons M, Raposo G. Exosomes–vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21(4):575–581. doi:10.1016/j.ceb.2009.03.007
  • Quesenberry PJ, Aliotta J, Deregibus MC, Camussi G. Role of extracellular RNA-carrying vesicles in cell differentiation and reprogramming. Stem Cell Res Ther. 2015;6:153. doi:10.1186/s13287-015-0150-x
  • Mopin A, Driss V, Brinster C, Detailed A. Protocol for characterizing the murine C1498 cell line and its associated leukemia mouse model. J Vis Exp. 2016;116.
  • Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–579. doi:10.1038/nri855
  • Yao Y, Wang C, Wei W, et al. Dendritic cells pulsed with leukemia cell-derived exosomes more efficiently induce antileukemic immunities. PLoS One. 2014;9(3):e91463. doi:10.1371/journal.pone.0091463
  • Tu TC, Brown NK, Kim TJ, et al. CD160 is essential for NK-mediated IFN-gamma production. J Exp Med. 2015;212(3):415–429. doi:10.1084/jem.20131601
  • Vigano S, Banga R, Bellanger F, et al. CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression. PLoS Pathog. 2014;10(9):e1004380. doi:10.1371/journal.ppat.1004380
  • Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans. 2013;41(1):245–251. doi:10.1042/BST20120265
  • Huang F, Wan J, Hao S, Deng X, Chen L, Ma L. TGF-beta1-silenced leukemia cell-derived exosomes target dendritic cells to induce potent anti-leukemic immunity in a mouse model. Cancer Immunol Immunother. 2017;66(10):1321–1331. doi:10.1007/s00262-017-2028-5
  • Wallace JA, O’Connell RM. MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts. Blood. 2017;130:11. doi:10.1182/blood-2016-10-697698
  • Agha DM, Rouas R, Najar M, et al. Identification of acute myeloid leukemia bone marrow circulating MicroRNAs. Int J Mol Sci. 2020;21(19).
  • Agha DM, Rouas R, Najar M, et al. Impact of bone marrow miR-21 expression on acute myeloid leukemia T lymphocyte fragility and dysfunction. Cells. 2020;9:9. doi:10.3390/cells9071640
  • Lulla P, Naik S, Vasileiou S, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant. Blood. 2020. doi:10.1182/blood.2020009471